HC Wainwright Estimates Cibus’ FY2029 Earnings (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS) – Analysts at HC Wainwright upped their FY2029 EPS estimates for shares of Cibus in a report released on Friday, March 27th. HC Wainwright analyst A. Dayal now expects that the company will earn $0.31 per share for the year, up from their previous estimate of $0.27. The consensus estimate for Cibus’ current full-year earnings is ($2.96) per share. HC Wainwright also issued estimates for Cibus’ FY2030 earnings at $2.12 EPS.

Several other equities analysts also recently weighed in on the company. Jefferies Financial Group boosted their target price on Cibus from $1.90 to $3.00 and gave the company a “hold” rating in a research report on Wednesday, March 25th. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price target on shares of Cibus in a research report on Monday, December 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cibus in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.00.

Cibus Stock Performance

Shares of CBUS stock opened at $1.88 on Monday. The company has a market cap of $102.05 million, a PE ratio of -0.63 and a beta of 1.62. Cibus has a 1 year low of $1.09 and a 1 year high of $4.19. The stock’s 50 day simple moving average is $2.71 and its two-hundred day simple moving average is $1.95. The company has a debt-to-equity ratio of 1.37, a current ratio of 0.72 and a quick ratio of 0.72.

Cibus (NASDAQ:CBUS) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.01. Cibus had a negative return on equity of 174.58% and a negative net margin of 3,492.30%.The company had revenue of $1.06 million during the quarter, compared to analyst estimates of $1.64 million.

Hedge Funds Weigh In On Cibus

Hedge funds and other institutional investors have recently made changes to their positions in the company. Certior Financial Group LLC raised its holdings in shares of Cibus by 6.5% in the third quarter. Certior Financial Group LLC now owns 184,786 shares of the company’s stock valued at $238,000 after acquiring an additional 11,230 shares in the last quarter. Transce3nd LLC lifted its stake in Cibus by 29.1% in the second quarter. Transce3nd LLC now owns 52,656 shares of the company’s stock worth $75,000 after acquiring an additional 11,861 shares during the period. Geode Capital Management LLC grew its holdings in Cibus by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 275,180 shares of the company’s stock worth $479,000 after acquiring an additional 12,467 shares in the last quarter. Raymond James Financial Inc. increased its position in Cibus by 31.0% during the 2nd quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock valued at $74,000 after purchasing an additional 12,722 shares during the period. Finally, PACK Private Wealth LLC purchased a new position in Cibus during the 4th quarter valued at about $27,000. Institutional investors own 33.81% of the company’s stock.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.